Compare ProShares Bitcoin ETF (BITO) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares Bitcoin ETF vs ResMed Inc. — how do they compare? ProShares Bitcoin ETF trades at $8.58, while ResMed Inc. trades at $222.39 (market cap $31.92B). The key difference: ResMed Inc. pays a 1.2% dividend while ProShares Bitcoin ETF pays none, and ResMed Inc. is trading nearer its 52-week high, ProShares Bitcoin ETF nearer its low. Which is the better fit depends on your goals.
| BITO | RMD | |
|---|---|---|
Sector | Crypto-linked | Health |
52-Week High | $22.27 | $293.73 |
52-Week Low | $7.98 | $182.82 |
Market Cap | — | $31.92B |
Enterprise Value | — | $31.28B |
Dividend Yield | — | 1.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BITO trades at $8.79, up 1.03% with a bullish technical signal from moving averages. The ETF maintains a consistent dividend distribution pattern with recent $0.01 payouts. Technical indicators show neutral oscillators but overall positive momentum, with support and resistance clustered around $9. The fund's performance reflects ongoing investor interest in Bitcoin exposure vehicles despite market volatility.
BITO faces structural challenges with higher fees impacting long-term returns compared to spot Bitcoin ETFs. Recent analyst coverage highlights tactical utility but questions buy-and-hold suitability. The fund's correlation breakdown with high-beta equities and persistent crypto market headwinds present significant risk factors for investors seeking sustained growth.
ResMed (RMD) trades at $211.94, down 5.06% on the day, following a Q4 2026 earnings beat but weaker fiscal 2027 revenue guidance. The stock shows strong fundamentals with a 26.94% net income margin and consistent earnings beats, while technical indicators are neutral with support at $204 and resistance at $218. Recent news highlights growth in sleep device demand but concerns over sales forecasts.
Outlook remains mixed: robust profitability and a $235 consensus price target suggest upside, but near-term pressure from guidance and technical neutrality poses risks. Investors should weigh solid financial health against market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ProShares Bitcoin ETF
BITO offers exposure to Bitcoin returns primarily through Bitcoin futures contracts. It provides a regulated way for investors to trade Bitcoin performance within a traditional brokerage account without direct ownership.
Read more on BITO →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
